The pharmacological profile of a specific,safe, effective and non-sedative anti-allergic,astemizole |
| |
Authors: | C. J. E. Niemegeers F. Awouters P. A. J. Janssen |
| |
Affiliation: | (1) Janssen Pharmaceutica Research Laboratories, B-2340 Beerse, Belgium |
| |
Abstract: | In the compound 48/80 lethality test in rats, which is based on the specific activation of mast cells, astemizole was selected as a potent, long-acting and orally very effective inhibitor of anaphylactoid shock. In comparison to other histamine-H1 antagonists astemizole was also a very effective inhibitor of allergic reactions in rats and dogs and remarkably free of non-specific interactions with other biological amines and normal body functions. In numerous tests no evidence of central activity was found and toxicity studies have shown astemizole to be a very safe drug despite of its long duration of action. A daily dose of 10 mg of astemizole was found clinically free of side-effects and more effective than conventional antihistamine treatment. |
| |
Keywords: | |
本文献已被 SpringerLink 等数据库收录! |
|